#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Prostate cancer Obesity Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Malignant melanoma Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rett syndrome Amyotrophic lateral sclerosis gene carrier Exudative retinopathy Cardiac sarcoidosis Myeloid leukaemia Primary amyloidosis Hidradenitis Fusarium infection Encephalitis autoimmune Thromboangiitis obliterans Oesophageal squamous cell carcinoma stage II Dupuytren's contracture Transitional cell carcinoma Peritoneal neoplasm Osteochondrodysplasia More trials…

    Learn about Rare Diseases

    Bronchiolitis obliterans syndrome – Basic Information Nephroblastoma – Diagnostics Prader-Willi syndrome – Treatment Mucopolysaccharidosis Sarcoma – Life with Disease Ewing’s sarcoma metastatic – Life with Disease Hereditary neuropathic amyloidosis – Life with Disease Primary biliary cholangitis – Basic Information Synovial sarcoma recurrent – Life with Disease Activated PI3 kinase delta syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Talquetamab Tamoxifen Clobetasol Glepaglutide Cefuroxime Human Serum Albumin 5% Anb032 Carbetocin Omeprazole Bexotegrast Mosaic Hbcoreag Amsacrine Polatuzumab Vedotin ULTEVURSEN CICLOPIROX Tetracaine Hydrochloride Mepacrine Regn7257 YOHIMBINE HYDROCHLORIDE Amb-05X More therapies…

    Learn about Your Condition

    Oesophageal atresia Marfan's syndrome Hepatitis D Colon cancer stage IV Chorioretinitis Immune-mediated renal disorder Lymphangioleiomyomatosis Trisomy 21 Ophthalmoplegia Haemorrhage Short-bowel syndrome Metastatic gastric cancer Progressive multiple sclerosis Skin papilloma Medulloblastoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego…

Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego W Katowicach

Ul. Ceglana 35, Katowice, 40-514, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mk-1084
    • Durvalumab
    France Germany Greece Italy The Netherlands Poland +1

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    Austria Belgium Bulgaria France Germany Greece +8

  • Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Carboplatin
    • Etoposide
    • Igg-Like T Cell Engager Binding To Dll3 And Cd3
    Austria Belgium Czechia Denmark Finland France +8

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE
    • Tucatinib
    • Capecitabine
    Austria Belgium Czechia France Germany Hungary +5

  • A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    • Paclitaxel Albumin-Bound
    Czechia France Germany Greece Hungary Italy +2

  • A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Everolimus
    Austria Belgium France Germany Italy The Netherlands +2

  • A Study to Test if Rinvecalinase Alfa is Safe and Works for Treating Acute Ischemic Stroke in Patients with Moderate Stroke Severity

    Recruiting

    4 1
    Investigated Diseases:
    • Ischaemic stroke
    Belgium France Hungary Poland Romania Spain

  • Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

    Recruiting

    3 1
    Investigated Diseases:
    • Carcinoid syndrome
    Investigated Drugs:
    • Paltusotine
    Belgium Denmark France Germany Ireland Italy +4

  • Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive biliary tract cancer
    Investigated Drugs:
    • Cisplatin
    • Durvalumab
    • Gemcitabine
    Austria Belgium Czechia France Germany Italy +4
1 2 3 … 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!